Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in … Read more
Annexon Inc (ANNX) - Total Liabilities
Latest total liabilities as of September 2025: $67.70 Million USD
Based on the latest financial reports, Annexon Inc (ANNX) has total liabilities worth $67.70 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Annexon Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Annexon Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Annexon Inc Competitors by Total Liabilities
The table below lists competitors of Annexon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scientech Corp
TW:3583
|
Taiwan | NT$17.49 Billion |
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
China | CN¥2.43 Billion |
|
Interfor Corporation
PINK:IFSPF
|
USA | $1.45 Billion |
|
Dateline Resources Ltd
AU:DTR
|
Australia | AU$4.38 Million |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
China | CN¥785.33 Million |
|
Care Property Invest NV
BR:CPINV
|
Belgium | €689.08 Million |
|
Integra LifeSciences Holdings
NASDAQ:IART
|
USA | $2.61 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Annexon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annexon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annexon Inc (2017–2024)
The table below shows the annual total liabilities of Annexon Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $56.97 Million | +20.90% |
| 2023-12-31 | $47.12 Million | -12.59% |
| 2022-12-31 | $53.90 Million | -2.23% |
| 2021-12-31 | $55.13 Million | +372.50% |
| 2020-12-31 | $11.67 Million | +83.23% |
| 2019-12-31 | $6.37 Million | -37.99% |
| 2018-12-31 | $10.27 Million | -80.99% |
| 2017-12-31 | $54.03 Million | -- |